



## Comparative Bioavailability of Two Digoxin Formulations: Determination in Human Plasma by Microparticle Enzyme Immunoassay

Eduardo A. JUNIOR <sup>1,2\*</sup>, Luciana F. DUARTE <sup>1</sup>, Moisés L.P. VANUNCI <sup>1</sup>,  
Lara C. SILVA <sup>1</sup>, Renata PEREIRA <sup>1</sup>, Silvana CALAFATTI <sup>3</sup> & José P. JUNIOR <sup>3</sup>

<sup>1</sup> *Scentryphar Clinical Research, Av. Barão de Itapura, 885, 13020-420, Campinas-SP, Brazil.*

<sup>2</sup> *Unicamp - College of Medical Sciences - Department of Medical Clinic/Cardiologia,  
Rua Tessalia Vieira de Camargo, 126, 13083-970, Barão Geraldo, Campinas-SP, Brazil.*

<sup>3</sup> *Clinical Pharmacology and Gastroenterology Unit, São Francisco University,  
Av. São Francisco de Assis, 218, 12916-900, Jardim São José, Bragança Paulista-SP, Brazil.*

**SUMMARY.** The present study was performed to compare the bioavailability of two digoxin 0.25 mg tablet formulation in 30 volunteers of both sexes. The study was conducted open with randomized two period crossover design and a three-week washout period. Plasma samples were obtained over a 144 h interval. Digoxin concentrations were analyzed by a validated microparticle enzyme immunoassay with optical detection by fluorescence. Bioequivalence between the products was determined by calculating 90 % confidence intervals (90 % I.C) for the ratio of  $AUC_{0-72h}$  and  $C_{max}$  values for the test and reference products, using logarithmic transformed data. The 90 % confidence intervals were 86.98–118.33 %, and 84.52–98.76 %, respectively. Since the 90 % confidence intervals for  $C_{max}$  and  $AUC_{0-72h}$  were within the 80–125 % interval proposed by Food and Drug Administration, it was concluded that the two Digoxin formulations are bioequivalent in their rate and extent of absorption.

**KEY WORDS:** Bioequivalence, Digoxin, Pharmacokinetics, Volunteers.

\* Author to whom correspondence should be addressed. *E-mail:* eabib@scentryphar.com